Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs TG Therapeutics Inc (TGTX) Price & Performance

FLRN trades at $30.77, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend with moving averages and ADX suggesting selling pressure, though RSI near 20 indicates potential oversold conditions. The company has maintained consistent dividend payments of $0.11 per share throughout 2026, providing income stability for shareholders despite the challenging technical backdrop.

The stock faces headwinds from bearish technical momentum while offering dividend stability. Investment opportunity exists for income-focused investors attracted to the consistent dividend yield, though technical weakness suggests near-term price pressure. Key risks include broader market volatility and the stock's inability to break through resistance levels amid current bearish sentiment.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.